Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge

Biochemistry

Volumn 36, Issue 9, 1997, Pages 2679-2685

  Lampidis, T J ^a   Kolonias, D ^a   Podona, T ^a   Israel, M ^b   Safa, A R ^c   Lothstein, L ^b   Savaraj, N ^a   Tapiero, H ^d   Priebe, W ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTHRACYCLINE DERIVATIVE; CELL NUCLEUS DNA; DOXORUBICIN; GLYCOPROTEIN P;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CELL ORGANELLE; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG ACCUMULATION; DRUG TARGETING; LEUKEMIA CELL; LIPOPHILICITY; MITOCHONDRION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

AFFINITY LABELS; ANIMALS; ANTHRACYCLINES; CELL LINE; CELL NUCLEUS; DRUG RESISTANCE, MULTIPLE; FIBROBLASTS; GROWTH INHIBITORS; INTRACELLULAR FLUID; LIPID METABOLISM; MYOCARDIUM; P-GLYCOPROTEIN; RATS; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0031017789     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi9614489     Document Type: Article

References (25)

1. Arcamone, F. (1981) in Doxorubicin Anticancer Antibiotics, Vol. 17, Academic Press, New York.
2. Baguely, B. C., & Finlay, G. (1988) Eur. J. Cancer, 24, 205-210.
3. Beck, W. T. (1987) Biochem. Pharmacol. 36, 2879-2887.
4. Beck, W. T. (1990) Cancer Treat. Rev. 17 (Suppl. A), 11-20.
5. Dellinger, M., Pressman, B., Higgenson, C., Kolonias, D., Savaraj, N., Tapiero, H., & Lampidis, T. J. (1992) Cancer Res. 52, 6385-6389.
6. Ford, J. M., Prozialeck, W. C., & Hait, W. N. (1989) Mol. Pharmacol. 35, 105-15.
7. Friche, E., Demant, E. J., Sehested, M., Nissen, N.I. (1993) Br. J. Cancer, 67, 226-231.
8. Gerlach, J. H., Kartner, N., Bell, D. R., & Ling, V. (1986) Cancer Surveys 5, 25-45.
9. Israel, M., Seshadri, R., Koseki, Y., Sweatman, & Idris, J. M. (1988) Cancer Treat. Rev. 14, 163-167.
10. Kartner, N., & Ling, V. (1989) Sci. Am. 260, 44-51.
11. Kiue, A., Sato, T., Suzuki, K., Inada, H., Okumura, M., Kikuchi, J., Sato, S, Kohno, J. & Kuwano, M. (1990) Cancer Res. 50, 310-317.
12. Lampidis, T. J., Henderson, L. C., Israel, M., & Canellos, G. P. (1980) Cancer Res. 40, 3901-3909.
13. Lampidis, T. J., Munck, J. N., Krishan, A., & Tapiero, H. (1985) Cancer Res. 46, 2626-2631.
14. Lampidis, T. J., Castello, C., Giglio, A. D., Savaraj, N., & Tapiero, H. (1989) Biochem. Pharm. 38, 4267-4271.
15. Lothstein, L., Hosey, L. M., Sweatmnan, T. W., Koseki, Y., Dockter, M., & Priebe, W. (1993) Oncol. Res. 5, 229-234.
16. Lothstein, L., Sweatmnan, T. W., & Priebe, W. (1995) Med. Chem. Lett. 5, 1807-1812.
17. Lown, J. W. (1988) Anthracycline and anthracenedione-based anticancer agents. Bioactive molecules, Vol. 6, Elsevier Science Pub., Amsterdam, Oxford, New York, Tokyo.
18. Pearce, H. L., Safa, A. R., Bach, N. J., Winter, M. A., Cirtain, M. C., & Beck, W. T. (1989) Proc. Natl. Acad. Sci. U.S.A. 86, 5128-5132.
19. Priebe, W., Przewloka, T., Fokt, I., Perez-Soler, R., & Safa, A. R. (1995) Am. Assoc. Cancer Res. 36, 334 (abstract 1989).
20. Priebe, W. (1995) (1995) Anthracycline Antibiotics, Novel Analogues, Methods of Delivery and Mechanisms of Action, American Chemical Society, Washington D.C.
21. Safa, A. R. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 7187-7191.
22. Safa, A. R. (1993) Cancer Invest. 11, 46-53.
23. Safa, A. R., Glover, C. J., Meyers, M. B., Biedler, J. L., & Felsted, R. L. (1986) J. Biol. Chem. 261, 6137-6140.
24. Sehested, M., Jensen, P. B., Skovsgaard, T., Bindslev, N., Demant, E. J., Friche, E., & Vindelov, L. (1989) Br. J. Cancer 60, 809-814.
25. Tapiero, H., Munck, J. N., Benoun, M., Foucade, A., & Lampidis, T. J. (1984) Cancer Res. 44, 5544-5549.